



NATIONAL INSTITUTE FOR PHARMACEUTICAL RESEARCH & DEVELOPMENT (NIPRD)

Office of The Director General/Chief Executive Officer

NIPRD/DG/NASENI/2025/04

October 28, 2025

The Executive Vice-Chairman/Chief Executive,
National Agency for Science and Engineering Infrastructure (NASENI),
The Presidency,
Idu Industrial Layout,
Abuja.

LETTER OF ENDORSEMENT FOR THE NASENI RESEARCH COMMERCIALIZATION GRANTS PROGRAMME (NRCGP)

This is to convey the compliments of the Management and Staff of the National Institute for Pharmaceutical Research and Development (NIPRD) to the Executive Vice-Chairman/Chief Executive, National Agency for Science and Engineering Infrastructure (NASENI).

2. I am pleased to write in support of Dr. Olubunmi J. Olayemi, Deputy Director (Research), Department of Pharmaceutical Technology and Raw Materials Development (PT&RMD), NIPRD and the Principal Investigator for the NRCGP application proposal titled '**SCALING UP PRODUCTION OF A PLANT-BASED ANTIFUNGAL OINTMENT: A Health Innovation for Accessible and Affordable Fungal Infection Treatment**'.

3. NIPRD is a reputable public health research institute with a track record of excellence in pharmaceutical research, drug development, healthcare innovations. The Institute has continued to demonstrate competence, accountability, and a commitment to advancing Nigeria's health sector through innovative research and capacity development.

4. The proposed project seeks to strengthen health innovation and pharmaceutical research, which aligns with the Presidential Initiative on Unlocking the Healthcare Value Chain, as well as Federal Government's priorities on improving healthcare delivery, promoting local content, and supporting Nigeria's journey towards self-reliance in healthcare innovation, improved access to medicines, and national socio-economic development

5. We hereby affirm our endorsement of Dr. Olayemi's grant proposal and recommend it for consideration.

6. Please accept the assurances of my highest regards for your person and office.

Dr. Obi Adigwe, NPOM, FNAPharm, FAPH, FPCPharm, FPSN,
Director-General/Chief Executive Office

